AI-powered lung cancer screening

Fewer missed cancers. Fewer unnecessary biopsies.

Lung cancer screening has two problems: finding eligible patients (20 pack-year history) and diagnosing nodules accurately.

We built AI for both: Select a product to learn more

LungAI Hospitals Payors
Malignancy probability scoring for every lung nodule on LDCT. Reimbursable under CPT 0721T (HOPPS) following FDA 510(k) clearance
LungIQ FQHCs Hospitals Payors
Finds screening-eligible patients by estimating smoking history (20 pack-year requirement) from EHR clinical notes
Contact us See how it works for hospitals
Axial CT scan showing lung nodule with LungAI overlay
2
Non-solid
Baseline
10.9 mm, 619 mm³
Malignancy Risk: 31.7
Baseline
#103/An103(F2M)
Raysum
TH 0.8 mm
WW 1500
WL -700
LungAI CADx
Sharp
Missed cancer identified

Lung-RADS categorized this nodule as 2 (benign appearance), recommending annual follow-up only. LungAI scored it 31.7 malignancy risk. Later confirmed malignant.

Dashboard Patients Reports Settings
Patient Finder
Eligible Queue
Outreach
Screening Status
Analytics
EHR Sync
847Eligible patients found
312Awaiting outreach
94%Match accuracy
Recently Identified
LIVE
PatientPack-YearsAgeRisk
M. Thompson3261High
R. Garcia2557High
J. Williams2864Medium
S. Chen2253Medium
D. Okafor2058Low

*Screen image is a simulated representation of LungAI output as it would appear within a third-party CADe viewer. Actual product appearance may vary. LungAI performance data from internal retrospective validation on NLST held-out data. LungAI is an investigational clinical decision support tool and does not replace physician judgment.

LungAI is an investigational medical device and has not been cleared by FDA. Oatmeal Health is preparing a 510(k) premarket notification for submission to FDA. LungAI is not commercially available in the United States. Clinical performance data reflect retrospective studies on held-out datasets; results may differ in prospective use.
The reality of lung cancer in America

The numbers that make early detection urgent

131,880

Americans die from lung cancer every year, more than breast, colon, and prostate combined

18%

Of eligible Americans are currently screened for lung cancer each year

~80%

Of lung cancers are still diagnosed at late stage, when 5-year survival is under 9%

64.7%

5-year survival rate when lung cancer is caught early at Stage I or II

14-20M+

Americans are eligible for free annual LDCT screening

<6%

Screened in underserved FQHC communities, where the gap is widest

Sources: ACS Cancer Facts 2024, USPSTF 2021, NLST, NCI SEER

How It Works

One platform. Three partners.
Every patient found.

Lung cancer screening fails because the system is fragmented. FQHCs have the patients. Hospitals have the scanners. Payers have the incentive. We connect all three.

Community Health Centers
Find the patients no one else finds
FQHCs serve 34M+ lives, many with the highest smoking prevalence and lowest screening rates. LungIQ scans EHR data to identify eligible patients, even when smoking history was never entered into structured fields.
  • LungIQ 0.97 AUROC patient identification
  • 9x faster than manual chart review
  • Eligible patients referred to partner imaging centers
  • Reimbursable shared decision-making visits (G0296)
Find hidden patients
Hospitals & Imaging Centers
Screen more patients. Diagnose with confidence.
Hospitals receive a steady referral pipeline from FQHC partners. Post-FDA clearance, LungAI adds a reimbursable AI diagnostic layer inside the radiologist's existing viewer. No new workstation. No new login.
  • LungIQ Identify eligible patients in-system too
  • LungAI Malignancy scoring 0 to 100, per nodule
  • New revenue via CPT 0721T (post-FDA clearance)
  • Fewer missed cancers. Fewer unnecessary biopsies.
Review the evidence
*Pre-FDA 510(k) clearance. NLST held-out retrospective study. Results may differ in prospective clinical use.
Health Plans
Turn screening spend into measurable savings
LDCT screening is already an ACA-mandated benefit. Payers are paying for it. The question is what they're getting from it. Earlier detection shifts costs from $200K+ per patient (Stage IV) to $54K (Stage I).
  • No new coverage policy or billing model required
  • 4 to 6x ROI from early detection vs late-stage treatment
  • HEDIS lung screening measure expected (NCQA)
  • Claims-validated PMPM model, built with your actuaries
Partner with us
Jonathan Govette, CEO and Co-Founder of Oatmeal Health
Our CEO's Story
A mission born from personal loss
After losing more than ten family members to cancer, Jonathan Govette founded Oatmeal Health to make sure fewer families have to endure the same. We built the platform we wish had existed.
Read our story →
"
We can defuse the cancer time bomb, but only if we find people earlier.
Jonathan Govette CEO and Co-Founder

Ready to close the lung cancer screening gap in your community?

Whether you're an FQHC, health system, or health plan, we have a program built for you.

Partner with us